Macleods Pharma USA ,inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Macleods Pharma USA ,inc Pharmaceutical Import Records from India — 12 Products, $40.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Macleods Pharma USA ,inc — Pharmaceutical Importer Profile (2026) | 12 Products, $40.1M Trade | TransData Nexus

Macleods Pharma USA ,inc

Pharmaceutical Importer · United States · Cardiovascular Focus · $40.1M Total Trade · DGFT Verified

Macleods Pharma USA ,inc is a pharmaceutical importer based in United States with a total trade value of $40.1M across 12 products in 9 therapeutic categories. Based on 1,138 verified import shipments from Indian Customs (DGFT) records, Macleods Pharma USA ,inc is the #1 buyer in 1 product including Levothyroxine. Macleods Pharma USA ,inc sources from 1 verified Indian supplier, with Macleods Pharmaceuticals Limited accounting for 100.0% of imports.

Macleods Pharma USA ,inc — Import Portfolio & Supplier Network

Macleods Pharma USA ,inc import network — 12 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Macleods Pharma USA ,inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Macleods Pharmaceuticals Limited	$26.1M	1,193	100.0%

Macleods Pharma USA ,inc sources from 1 verified Indian supplier across 549 distinct formulations. The sourcing is highly concentrated — Macleods Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Drugs and pharmaceuticals harmless	$7.7M	292
Medicines. emtricitabine 200MG +	$546.2K	13
Irbesartan 150MG and hydrochlorothiazide	$336.6K	13
Irbesartan 300MG and hydrochlorothiazide	$232.5K	7
Drugs and pharmaceuticals harmless medicines valsartan and hydrochlorothiazide tablets USP (320 MG/ 25 MG)	$204.1K	10
Drugs and pharmaceuticals harmlessmedicines candesartan cilexetil and hydrochlorothiazide tablets USP (32 MG	$200.0K	4
Olmesartan 40MG tablets - ndc no.33342-180-10 Pack	$181.0K	5
Olanzapine tablets USP 5 MG 30 ct- ndc no. 33342-068-07 Pack	$171.1K	6
Irbesartan tablets USP 300 MG 1x90s (51428 pac	$150.0K	3
Medicines. sevelamer carbonate 800MG tablets (net 2726.7840 kgs sevelamer carbonate)	$150.0K	3
Drugs and pharmaceuticals harmlessmedicines valsartan and hydrochlorothiazide tablets USP (320 MG/ 25 MG)	$150.0K	3
Drugs and pharmaceuticals harmlessmedicines valsartan and hydrochlorothiazide tablets USP (320 MG/ 12.5 MG)	$144.4K	4
Drugs and pharmaceuticals harmlessmedicines valsartan and hydrochlorothiazide tablets USP (160 MG/ 25 MG)	$141.5K	4
Drugs and pharmaceuticals harmlessmedicines valsartan and hydrochlorothiazide tablets USP (160 MG/ 12.5 MG)	$140.8K	4
Drugs and pharmaceuticals harmless medicines emtricitabine and tenofovir disoproxil fumarate tablets (200 MG/ 300 MG	$137.6K	3

Import Portfolio — Top 12 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Hydrochlorothiazide	Diuretics	$13.5M	343	1.0%	6
2	Valsartan	Cardiovascular	$10.6M	228	1.2%	2
3	Irbesartan	Cardiovascular	$6.5M	150	3.5%	6
4	Pioglitazone	Diabetes & Endocrine	$2.3M	178	2.4%	10
5	Montelukast	Respiratory	$2.0M	41	1.2%	2
6	Amlodipine	Cardiovascular	$1.9M	37	0.0%	16
7	Emtricitabine	Antiviral & HIV Medications	$981.1K	20	0.8%	18
8	Levothyroxine	Diabetes & Endocrine	$800.0K	16	1.0%	1
9	Nystatin	Antifungals	$751.1K	96	0.6%	16
10	Celecoxib	Analgesics & Antipyretics	$550.0K	11	0.4%	2
11	Repaglinide	Advanced Diabetes Medications	$118.1K	6	1.7%	15
12	Niacin	Lipid & Metabolism	$71.4K	12	1.4%	11

Macleods Pharma USA ,inc imports 12 pharmaceutical products across 9 categories into United States totaling $40.1M. The company is the #1 buyer for 1 product: Levothyroxine.

Macleods Pharma USA ,inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Macleods Pharma USA Inc is a pharmaceutical importer and distributor based in the United States, specializing in the procurement and distribution of finished pharmaceutical formulations. The company is a subsidiary of Macleods Pharmaceuticals Limited, a prominent Indian pharmaceutical manufacturer. Macleods Pharma USA Inc plays a significant role in the U.S. pharmaceutical supply chain by providing a range of generic medications across various therapeutic categories.

The company's headquarters are located at 666 Plainsboro Road, Building 200, Suite 230, Plainsboro, NJ 08536-3030. This strategic location positions Macleods Pharma USA Inc to effectively serve the U.S. market, leveraging proximity to major distribution hubs and facilitating efficient logistics operations. The company employs a dedicated team focused on ensuring the timely and compliant importation of pharmaceutical products from India to the United States.

2Distribution Network

Macleods Pharma USA Inc operates a centralized distribution model from its headquarters in Plainsboro, New Jersey. While specific warehouse locations are not publicly disclosed, the company's strategic position in New Jersey enables efficient access to major transportation routes, including highways and ports, facilitating prompt distribution across the United States. The company collaborates with third-party logistics providers to manage warehousing and distribution, ensuring compliance with U.S. regulatory standards and maintaining the integrity of pharmaceutical products throughout the supply chain.

3Industry Role

In the U.S. pharmaceutical supply chain, Macleods Pharma USA Inc functions primarily as a pharmaceutical importer and distributor. The company sources finished pharmaceutical formulations from its parent company, Macleods Pharmaceuticals Limited in India, and distributes these products to various stakeholders within the U.S. healthcare system. By focusing on the importation and distribution of generic medications, Macleods Pharma USA Inc contributes to enhancing the accessibility and affordability of essential drugs in the U.S. market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Macleods Pharma USA ,inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Macleods Pharma USA Inc demonstrates a high degree of sourcing concentration, with a total import value of $40.1 million USD from India, accounting for 1,138 shipments. All imports are sourced from a single supplier, Macleods Pharmaceuticals Limited, indicating a strategic choice to maintain a streamlined supply chain and potentially leverage favorable terms. However, this single-source dependency may pose risks related to supply chain disruptions, such as manufacturing issues or regulatory challenges affecting the supplier. The company's consistent import volume suggests a stable and ongoing relationship with Macleods Pharmaceuticals Limited, which is crucial for maintaining uninterrupted product availability in the U.S. market.

2Supply Chain Resilience

The resilience of Macleods Pharma USA Inc's supply chain is closely tied to the operational stability of Macleods Pharmaceuticals Limited in India. The company imports a diverse portfolio of 549 unique formulations across 12 products and 9 therapeutic categories, indicating a broad sourcing strategy that can mitigate risks associated with single-product dependencies. However, the reliance on a single supplier for all imports means that any disruptions in Macleods Pharmaceuticals Limited's manufacturing processes, such as the recall of products due to manufacturing deviations, could impact Macleods Pharma USA Inc's ability to supply the U.S. market. To enhance supply chain resilience, Macleods Pharma USA Inc may consider diversifying its supplier base and establishing contingency plans to address potential disruptions.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth requirements for drug safety, efficacy, and quality. Pharmaceutical imports must comply with FDA regulations, including registration of foreign drug establishments, listing of drug products, and adherence to labeling and manufacturing standards. The FDA's import program ensures that all imported drugs meet U.S. standards for quality, safety, and effectiveness, protecting public health and maintaining the integrity of the U.S. drug supply chain.

2Import Licensing & GMP

To import pharmaceutical products into the United States, companies must ensure that their foreign suppliers are registered with the FDA and that their drug products are listed with the agency. The FDA requires that all imported drugs comply with current Good Manufacturing Practice (cGMP) standards, which are enforced to ensure the quality and safety of pharmaceutical products. Recognized cGMP certifications include those from the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Additionally, importers must obtain a wholesale distribution authorization, which involves meeting specific state and federal requirements to legally distribute pharmaceutical products within the U.S.

Macleods Pharma USA ,inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Macleods Pharma USA Inc's product strategy focuses on therapeutic areas such as cardiovascular, diuretics, and diabetes & endocrine, with the top five products accounting for 87.2% of their portfolio. This concentration suggests a strategic emphasis on high-demand medications in these categories, likely driven by market needs and the company's expertise. The significant import values of products like Hydrochlorothiazide, Valsartan, and Irbesartan indicate a strong presence in the cardiovascular segment, while the inclusion of Pioglitazone and Montelukast highlights a commitment to addressing diabetes and respiratory conditions. This targeted approach allows Macleods Pharma USA Inc to effectively serve specific patient populations and healthcare providers.

2Sourcing Profile

Macleods Pharma USA Inc's sourcing strategy is centered on importing finished pharmaceutical formulations from its parent company, Macleods Pharmaceuticals Limited in India. This approach leverages the manufacturing capabilities and regulatory compliance of Macleods Pharmaceuticals Limited, ensuring that products meet FDA standards. The focus on finished formulations allows Macleods Pharma USA Inc to streamline its operations and concentrate on distribution within the U.S. market. India's established pharmaceutical manufacturing industry, with its adherence to international quality standards, positions it as a reliable source for these products.

Market Positioning

Seller's Guide — How to Become a Supplier to Macleods Pharma USA ,inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Macleods Pharma USA Inc, especially in therapeutic areas where the company seeks to expand its portfolio or diversify its sourcing. Identifying gaps in Macleods Pharma USA Inc's current sourcing, such as specific formulations or dosage forms not currently imported, presents potential avenues for new suppliers. Establishing relationships with Macleods Pharma USA Inc could involve demonstrating compliance with FDA regulations, offering competitive pricing, and ensuring a reliable supply chain to meet the company's standards.

2Requirements & Qualifications

Indian exporters aiming to supply Macleods Pharma USA Inc and the broader U.S. market must ensure that their manufacturing facilities are registered with the FDA and that their products are listed with the agency. Compliance with cGMP standards, as recognized by the FDA, is mandatory. Additionally, products must meet FDA labeling requirements, including accurate and comprehensive information in English.

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Macleods Pharma USA ,inc

What products does Macleods Pharma USA ,inc import from India?

Macleods Pharma USA ,inc imports 12 pharmaceutical products across 9 categories. Top imports: Hydrochlorothiazide ($13.5M), Valsartan ($10.6M), Irbesartan ($6.5M), Pioglitazone ($2.3M), Montelukast ($2.0M).

Who supplies pharmaceuticals to Macleods Pharma USA ,inc from India?

Macleods Pharma USA ,inc sources from 1 verified Indian suppliers. The primary supplier is Macleods Pharmaceuticals Limited (100.0% of imports, $26.1M).

What is Macleods Pharma USA ,inc's total pharmaceutical import value?

Macleods Pharma USA ,inc's total pharmaceutical import value from India is $40.1M, based on 1,138 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Macleods Pharma USA ,inc focus on?

Macleods Pharma USA ,inc imports across 9 categories. The largest: Cardiovascular (47.3%), Diuretics (33.7%), Diabetes & Endocrine (7.7%).

Get Full Macleods Pharma USA ,inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 5 company name variants from customs records. For current shipment-level data, contact TransData Nexus.